-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Moderna is developing an mRNA vaccine against the endemic human coronavirus
On March 25, Moderna announced at its third annual Vaccine Day that it was preparing to develop a vaccine candidate (mRNA-1287) against the endemic human coronavirus (HCoV)
It targets four coronaviruses: HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1
The effects of these 4 coronaviruses on humans are not unpredictable and destructive, usually only causing common colds and upper respiratory tract infections
But for some high-risk groups (such as the elderly), viral infections can also lead to further serious illnesses, such as secondary bacterial infections and pneumonia
These four viruses are responsible for 10%-30% of upper respiratory tract infections globally and are the second most common cause of colds after rhinoviruses
"It would be a good idea to develop this vaccine if it could confer protection in high-risk groups, especially against seasonal respiratory viruses," said Luciana Borio, former acting chief scientist at the FDA
Moderna didn't disclose many details about its mRNA-1287 vaccine candidate and didn't respond to a request for comment, but the vaccine will likely be given as an intramuscular injection like other vaccines
However, data from the mRNA Covid-19 vaccine showed that intramuscular injections did not provide the lasting protection against coronavirus infection and symptomatic disease that one would like to see in a common cold vaccine
(Source: Internet, reference only)
